Physiogenex
  • About Us
    • Company overview
    • Management Team
    • Our values
    • Facilities
    • Partners
  • CRO Services
    • In vitro assays
    • Obesity – Insulin Resistance – Diabetes
    • NASH – Fibrosis
    • Diabetic Nephropathy
    • Fibrosis
    • Diabetic Neuropathy
    • GLP-1 Expertise
    • Immunometabolism
    • Dyslipidaemia Atherosclerosis
    • Nutraceuticals
    • Covid-19
  • Capabilities
    • In vivo metabolic studies
    • Ex vivo metabolic assays
    • Biochemical assays and histology analysis
    • Biological samples library
  • Consulting
  • Publications
  • News
  • careers
    • Spontaneous Application
    • Careers at Physiogenex
  • Contact us
Select Page
Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

by François Briand | Nov 29, 2018 | 2018

Physiogenex will be presenting radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the World Congress of Insulin Resistance (WCIR) 2018, in Los Angeles, CA, USA, November 29th – December 1st, 2018. The abstracts will be...
Physiogenex to present the effects of green coffee and green tea in DIO mice at Obesity Week 2018 in Nashville, TN, USA

Physiogenex to present the effects of green coffee and green tea in DIO mice at Obesity Week 2018 in Nashville, TN, USA

by François Briand | Nov 14, 2018 | 2018

Physiogenex will be presenting the effects of green coffee and green tea at the Obesity Week 2018, in Nashville, TN, USA, November 11-15th, 2018. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster...
Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

by François Briand | Nov 8, 2018 | 2018

Physiogenex will be presenting its 3-week ultra-fast NASH screening mouse model mouse at the Liver Meeting 2018, in San Francisco, November 9th-13th, 2018. The effects of GLP-1 receptor agonists in this innovative NASH mouse model will be presented by Dr. François...
Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.

Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.

by François Briand | Oct 26, 2018 | 2018

Physiogenex will be presenting its innovative animal models of diabetic nephropathy, namely the db/db mouse on high protein diet and the Unx/salt supplemented SDT fatty rat, at the ASN Kidney Week 2018, in San Diego, California. The studies, performed by Physiogenex...
Physiogenex to present at the Keystone Conference on Drivers of Type 2 Diabetes in Seoul, Korea – October 7-12th, 2018

Physiogenex to present at the Keystone Conference on Drivers of Type 2 Diabetes in Seoul, Korea – October 7-12th, 2018

by François Briand | Oct 7, 2018 | 2018

Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the...
Physiogenex to present at the AASLD single topic conference on hepatic fibrosis in Dallas, TX, USA, Sept. 14-15th 2018

Physiogenex to present at the AASLD single topic conference on hepatic fibrosis in Dallas, TX, USA, Sept. 14-15th 2018

by François Briand | Sep 14, 2018 | 2018

Physiogenex will be presenting a study dealing with the effects of obeticholic acid and elafibranor in various animal models of NASH/hepatic fibrosis. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster...
« Older Entries

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH/fibrosis, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications. For > 15 years, we have been evaluating the drugs’ efficacy of our clients using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated with our numerous co-publications with our industry partners.

For more information on our company and offers, please download our Corporate Presentation.

Menu

  • CRO Services
  • Consulting
  • Publications
  • News
  • Careers

Services

  • Obesity – Diabetes
  • NASH Preclinical
  • Dyslipidaemia Atherosclerosis
  • Diabetic Nephropathy
  • Nutraceuticals

Useful Menu

  • Accueil
  • Contact us
  • Site map
  • Legal mentions
  • Privacy Policy

Contact

PHYSIOGENEX S.A.S.

Address : 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
Phone : +33532097980

For general inquiries, please contact us here.

  • Twitter
  • RSS
Copyright © PHYSIOGENEX
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT